89 related articles for article (PubMed ID: 8608043)
21. Adjuvant therapy for breast cancer.
NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
[TBL] [Abstract][Full Text] [Related]
22. Multimodal exercise improves quality of life of women being treated for breast cancer, but at what cost? Randomized trial with economic evaluation.
Haines TP; Sinnamon P; Wetzig NG; Lehman M; Walpole E; Pratt T; Smith A
Breast Cancer Res Treat; 2010 Nov; 124(1):163-75. PubMed ID: 20734132
[TBL] [Abstract][Full Text] [Related]
23. [Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer].
Fagnani F; Colin X; Arveux P; Coudert B; Misset JL
Bull Cancer; 2007 Jul; 94(7):711-20. PubMed ID: 17723955
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer.
Retèl VP; Joore MA; Knauer M; Linn SC; Hauptmann M; Harten WH
Eur J Cancer; 2010 May; 46(8):1382-91. PubMed ID: 20359886
[TBL] [Abstract][Full Text] [Related]
25. Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal.
Chilcott J; Lloyd Jones M; Wilkinson A
Health Technol Assess; 2009 Jun; 13 Suppl 1():7-13. PubMed ID: 19567208
[TBL] [Abstract][Full Text] [Related]
26. Economic and cost-effectiveness issues in breast cancer treatment.
Hillner BE
Semin Oncol; 1996 Feb; 23(1 Suppl 2):98-104. PubMed ID: 8614853
[TBL] [Abstract][Full Text] [Related]
27. The cost effectiveness of tamoxifen in the prevention of breast cancer.
Noe LL; Becker RV; Gradishar WJ; Gore M; Trotter JP
Am J Manag Care; 1999 Jun; 5(6 Suppl):S389-406. PubMed ID: 10538851
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system.
Lux MP; Wöckel A; Benedict A; Buchholz S; Kreif N; Harbeck N; Kreienberg R; Kaufmann M; Beckmann MW; Jonat W; Hadji P; Distler W; Raab G; Tesch H; Weyers G; Possinger K; Schneeweiss A
Onkologie; 2010; 33(4):155-66. PubMed ID: 20389141
[TBL] [Abstract][Full Text] [Related]
29. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium.
Neyt M; Huybrechts M; Hulstaert F; Vrijens F; Ramaekers D
Health Policy; 2008 Aug; 87(2):146-59. PubMed ID: 18164510
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant endocrine therapy in post menopausal women: pharmacological evaluation using decision analysis approach in a Japanese hospital setting.
Miyazaki Y; Arakawa I; Inoue T
Gan To Kagaku Ryoho; 2009 Aug; 36(8):1299-309. PubMed ID: 19692769
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer.
Delea TE; Taneja C; Sofrygin O; Kaura S; Gnant M
Clin Breast Cancer; 2010 Aug; 10(4):267-74. PubMed ID: 20705558
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of 5 years of postoperative adjuvant tamoxifen therapy for Korean women with breast cancer: retrospective cohort study of the Korean breast cancer society database.
Yang JJ; Park SK; Cho LY; Han W; Park B; Kim H; Lee KS; Hahn SK; Cho SI; Ahn SH; Noh DY;
Clin Ther; 2010 Jun; 32(6):1122-38. PubMed ID: 20637966
[TBL] [Abstract][Full Text] [Related]
33. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.
Garrison LP; Lalla D; Brammer M; Babigumira JB; Wang B; Perez EA
Cancer; 2013 Sep; 119(17):3113-22. PubMed ID: 23775560
[TBL] [Abstract][Full Text] [Related]
34. When to recommend and to pay for first-line adjuvant breast cancer treatment? A structured review of the literature.
Kilian R; Porzsolt F
Breast; 2005 Dec; 14(6):636-42. PubMed ID: 16183288
[TBL] [Abstract][Full Text] [Related]
35. The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data.
Shiroiwa T; Fukuda T; Shimozuma K; Ohashi Y; Tsutani K
Breast Cancer Res Treat; 2008 Jun; 109(3):559-66. PubMed ID: 17661170
[TBL] [Abstract][Full Text] [Related]
36. Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis.
Norum J; Olsen JA; Wist EA; Lønning PE
Acta Oncol; 2007; 46(2):153-64. PubMed ID: 17453363
[TBL] [Abstract][Full Text] [Related]
37. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
Ward S; Pilgrim H; Hind D
Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
[TBL] [Abstract][Full Text] [Related]
38. Review of cost-effectiveness assessments of chemotherapy in adjuvant and advanced breast cancer.
Hillner BE
Anticancer Drugs; 1998 Nov; 9(10):843-7. PubMed ID: 9890695
[TBL] [Abstract][Full Text] [Related]
39. Breast cancer breakthrough in gene profilings?
Bateman C
S Afr Med J; 2009 Nov; 99(11):780-2. PubMed ID: 20218471
[No Abstract] [Full Text] [Related]
40. Should women with node-negative breast cancer receive adjuvant chemotherapy?--Insights from a decision analysis model.
Hillner BE; Smith TJ
Breast Cancer Res Treat; 1992; 23(1-2):17-27. PubMed ID: 1446048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]